Apelin improves myocardial performance in MCT-Induced pulmonary hypertension

• Type: Summary of Presentation in an International Conference
• Date: 2007

Authors

Falcão-Pires I (Author) FMUP; Henriques-Coelho T (Author) FMUP; Gonçalves N (Author) FMUP; Moreira-Gonçalves D (Author) Other; Leite-Moreira AF (Author) FMUP

Conference proceedings International

Title: Journal of the American College of Cardiology

Initial page: 74A

56th Annual Scientific Session of the American-College-of-Cardiology.

New Orleans, 24 a 27 de Mar de 2007

Scientific classification

FOS: Medical and Health sciences > Other medical sciences

Other information

Resumo (PT): Background: Apelin (AP) is the endogenous vasoactive ligand of APJ receptor. It’s widely expressed in the heart and lungs and has some cardiovascular functions such as endothelium-dependent vasodilatation and positive inotropic effect. The aim of this study was to evaluate the chronic effects of apelin administration on biventricular function in a model of pulmonary hypertension (PH) induced by monocrotaline (MCT). Methods: Male Wistar rats were randomly injected with MCT (60mg/Kg, sc) or vehicle (day 0). One week later, animals treated with MCT were randomly divided and treated with Pyr-apelin-13 (0.2mg/Kg/day, ip) or a similar volume of vehicle. The study resulted in 3 groups: CTRL; MCT and MCT+Apelin. At day 24, animals were instrumented to record right (RV) and left ventricle (LV) peak systolic (Pmax) and end-diastolic (ED) pressures, dP/dtmax, dP/dtmin, and time constant Tau. Also, heart and lungs were weighted. Results: Results are summarized on table 1 as mean±SEM. p<0,05: a vs CTRL; b vs MCT. Conclusions: Chronic administration of apelin has beneficial effects on MCT model namely, decreasing PH, right ventricle (RV) diastolic function and hypertrophy. These results reveal the importance of apelin-APJ system in the pathophysiology of PH, suggesting that apelin is a potential therapeutic target in this disease. CTRL MCT MCT+AP RV/LV+Septum (g/g) 0.205±0.05 0.59±0.04 a 0.40±0.06 a,b Lungs/body weight (g/Kg) 3.87±0.03 8.05±0.50 a 6.30±0.52 a,b RVPmax (mmHg) 22.2±1.93 45.2±3.34 a 30.8±2.77 a,b EDRV 1014±107 1646±90.7 a 1175±120 b PVDtele (mmHg) 0.8±0.3 1.9±0.66 2.4±0.31 a RV tau (ms) 26.6±2.1 22.1±1.96 13.5±0.90 b

Language: English

Type (Professor's evaluation): Scientific

Notes: American College of Cardiology – 56th Annual Scientific Session, published in journal, Journal of the American College of Cardiology 2007; 49(Suppl. A):74A.